Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Imaging tumour ATB0,+ transport activity by PET with the cationic amino acid O-2((2-[18F]fluoroethyl)methyl-amino)ethyltyrosine.

Müller A, Chiotellis A, Keller C, Ametamey SM, Schibli R, Mu L, Krämer SD.

Mol Imaging Biol. 2014 Jun;16(3):412-20. doi: 10.1007/s11307-013-0711-2. Epub 2013 Dec 5.

PMID:
24307544
2.

Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging.

Chiotellis A, Müller A, Weyermann K, Leutwiler DS, Schibli R, Ametamey SM, Krämer SD, Mu L.

Amino Acids. 2014 Aug;46(8):1947-59. doi: 10.1007/s00726-014-1754-7. Epub 2014 May 7.

PMID:
24802247
3.

Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy.

Karunakaran S, Umapathy NS, Thangaraju M, Hatanaka T, Itagaki S, Munn DH, Prasad PD, Ganapathy V.

Biochem J. 2008 Sep 15;414(3):343-55. doi: 10.1042/BJ20080622.

PMID:
18522536
4.

Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.

Chiotellis A, Mu L, Müller A, Selivanova SV, Keller C, Schibli R, Krämer SD, Ametamey SM.

Eur J Med Chem. 2013;70:768-80. doi: 10.1016/j.ejmech.2013.10.054. Epub 2013 Oct 30.

PMID:
24239624
5.

Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.

Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, Kitashoji T, Ohgaki R, Tanaka H, Endou H, Endo K, Sakurai H, Kanai Y.

J Nucl Med. 2012 Aug;53(8):1253-61. doi: 10.2967/jnumed.112.103069. Epub 2012 Jun 28.

6.

5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET.

Krämer SD, Mu L, Müller A, Keller C, Kuznetsova OF, Schweinsberg C, Franck D, Müller C, Ross TL, Schibli R, Ametamey SM.

J Nucl Med. 2012 Mar;53(3):434-42. doi: 10.2967/jnumed.111.096289. Epub 2012 Feb 13.

7.

Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.

Ohshima Y, Hanaoka H, Tominaga H, Kanai Y, Kaira K, Yamaguchi A, Nagamori S, Oriuchi N, Tsushima Y, Endo K, Ishioka NS.

Ann Nucl Med. 2013 May;27(4):314-24. doi: 10.1007/s12149-013-0687-7. Epub 2013 Jan 23.

PMID:
23337966
8.

Synthesis and biological evaluation of (18)F-labeled Fluoroethoxy tryptophan analogues as potential PET tumor imaging agents.

Chiotellis A, Muller A, Mu L, Keller C, Schibli R, Krämer SD, Ametamey SM.

Mol Pharm. 2014 Nov 3;11(11):3839-51. doi: 10.1021/mp500312t. Epub 2014 Jul 14.

PMID:
24988527
9.

Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.

Hutterer M, Ebner Y, Riemenschneider MJ, Willuweit A, McCoy M, Egger B, Schröder M, Wendl C, Hellwig D, Grosse J, Menhart K, Proescholdt M, Fritsch B, Urbach H, Stockhammer G, Roelcke U, Galldiks N, Meyer PT, Langen KJ, Hau P, Trinka E.

J Nucl Med. 2017 Jan;58(1):129-137. doi: 10.2967/jnumed.116.176610. Epub 2016 Jul 28.

PMID:
27469356
10.

Effect of α-Methyl versus α-Hydrogen Substitution on Brain Availability and Tumor Imaging Properties of Heptanoic [F-18]Fluoroalkyl Amino Acids for Positron Emission Tomography (PET).

Bouhlel A, Alyami W, Li A, Yuan L, Rich K, McConathy J.

J Med Chem. 2016 Apr 14;59(7):3515-31. doi: 10.1021/acs.jmedchem.6b00189. Epub 2016 Mar 23.

11.

Evaluation of D-isomers of O-18F-fluoromethyl, O-18F-fluoroethyl and O-18F-fluoropropyl tyrosine as tumour imaging agents in mice.

Tsukada H, Sato K, Fukumoto D, Kakiuchi T.

Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1017-24. Epub 2006 May 13.

PMID:
16699766
12.

Synthesis and evaluation of ¹⁸F labeled FET prodrugs for tumor imaging.

Wang L, Lieberman BP, Ploessl K, Kung HF.

Nucl Med Biol. 2014 Jan;41(1):58-67. doi: 10.1016/j.nucmedbio.2013.09.011. Epub 2013 Oct 9.

13.
14.
15.

Synthesis and comparative biological evaluation of L- and D-isomers of 18F-labeled fluoroalkyl phenylalanine derivatives as tumor imaging agents.

Wang L, Lieberman BP, Plössl K, Qu W, Kung HF.

Nucl Med Biol. 2011 Apr;38(3):301-12. doi: 10.1016/j.nucmedbio.2010.10.004. Epub 2010 Dec 3.

PMID:
21492778
16.
17.

Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery.

Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, Smith SB, Ganapathy V, Ganapathy ME.

J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47. Epub 2003 Nov 14.

18.

Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer.

Denoyer D, Kirby L, Waldeck K, Roselt P, Neels OC, Bourdier T, Shepherd R, Katsifis A, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):703-12. doi: 10.1007/s00259-011-2017-4. Epub 2011 Dec 13.

PMID:
22160176
19.

Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.

Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, Kato I, Hamase K, Nagamori S, Kanai Y.

Cancer Sci. 2015 Mar;106(3):279-86. doi: 10.1111/cas.12602. Epub 2015 Mar 6.

20.

Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.

Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1257-66. doi: 10.1007/s00259-011-1775-3. Epub 2011 Mar 23.

Supplemental Content

Support Center